Content Hub

enhurtu

NEWLY ADDED!

Strength, Weakness, Opportunity and Threat Analysis of Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for unresectable or metastatic HER2-positive breast cancer patients.

Hanson Wade

trod

NEWLY ADDED!

Strength, Weakness, Opportunity and Threat Analysis of Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC).

Hanson Wade

Francon Marincola

NEWLY ADDED!

CAR-TCR Presentation

CAR T Cells for Solid Tumours, To Do List

Francesco M. Marincola, Chief Research Officer, Refuge Biotechnologies

Hans-Peter Gerber

NEWLY ADDED!

CAR-TCR Presentation

Identification of Novel Shared Targets for Solid Tumors

Hans-Peter Gerber, Ph.D. SVP & CSO,3T Bioscience